Treats migraine. Sold as Aimovig. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Erenumab-Aooe (sold as Aimovig), first approved May 17, 2018, with 2 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Aimovig Autoinjector | Part D | $307M | +1% | 55,132 |
| Aimovig Pregnancy Exposure RegistryMigraine · Amgen | — | Recruiting | Nov 29, 2023 |
| Screening Trial for Pain Relief in Schwannomatosis (STARFISH)Schwannomatosis, Schwannomas · Massachusetts General Hospital | Phase 2 | Recruiting | Jan 13, 2023 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA